Payment & Shipping Terms:
|Purity:||99%||Storage:||Shading, Confined Preservation|
|Stock:||Enough Stock||Grade:||Pharma Grade|
Fine Chemicals Prednisolone-21-acetate CAS 52-21-1 White Steroids Powder
Product Name: Prednisolone-21-acetate
Synonyms: (11beta)-21-(Acetyloxy)-11,17-dihydroxypregna-1,4-diene-3,20-dione;11,17-Dihydroxy-3,20-dioxopregna-1,4-dien-21-yl acetate;11beta,17,21-Trihydroxypregna-1,4-diene-3,20-dione 21-acetate;21-(acetyloxy)-11,17-dihydroxy-4-diene-(11-beta)-pregna-20-dione;21-(acetyloxy)-11,17-dihydroxy-4-diene-(11beta)-pregna-20-dione;4-diene-3,20-dione,11-beta,17,21-trihydroxy-pregna-21-acetate;Ak-Tate;component of Blephamide liquifilm,
Product Categories: Biochemistry;Hydroxyketosteroids;Steroids;Intermediates & Fine Chemicals;Pharmaceuticals;API;METICOTOLONE;Applicable to rheumatoid arthritis, rheumatic fever, lupus erythematosus (sle), scleroderma, dermatomyositis, acute lymphocytic leukemia, etc
Synthetic corticosteroid; metabolically interconvertible with prednisone.
Prednisolone Acetate Ophthalmic Suspension USP, 1% is an adrenocortical steroid product prepared as a sterile ophthalmic suspension.
|Appearance & Physical State:||white crystalline powder|
|Boiling Point:||579.8ºC at 760mmHg|
|Refractive Index:||112 ° (C=1, Dioxane)|
|Stability:||Stable. Incompatible with strong oxidizing agents.|
INDICATIONS AND USAGE
Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies.
DOSAGE AND ADMINISTRATION
SHAKE WELL BEFORE USING. Two drops topically in the eye(s) four times daily. In cases of bacterial infections, concomitant use of anti-infective agents is mandatory. Care should be taken not to discontinue therapy prematurely. If signs and symptoms fail to improve after two days, the patient should be re-evaluated (SEE PRECAUTIONS).
The dosing of Prednisolone Acetate Ophthalmic Suspension USP, 1% may be reduced, but care should be taken not to discontinue therapy prematurely. In chronic conditions, withdrawal of treatment should be carried out by gradually decreasing the frequency of applications.